Massimo Di Gioia

TL;DR: Intense immunosuppression followed by AHSCT is significantly superior to MTX in reducing MRI activity in severe cases of MS, and these results strongly support further phase III studies with primary clinical endpoints.

TL;DR: This European multicenter study underlines the need for careful management and follow-up for secondary AD after HSCT and identifies Lupus erythematosus as primary AD, and antithymocyte globulin use plus CD34(+) graft selection were important risk factors for secondaryAD by multivariate analysis.

TL;DR: Recent reports confirm the evidence that HSCT is able to induce a high rate of sustained remissions in most severe autoimmune diseases, unresponsive to conventional treatments.

TL;DR: To confirm CXCL10 over production in bone marrow mesenchymal stem cells (MSCs) and circulating monocytes isolated from multiple sclerosis patients (MS) and identify predate cell molecular signature, and extend this analysis after autologous hematopoietic stem cell transplantation (AHSCT) to test if therapy has modifying effects on MSCs and circulate monocytes.

TL;DR: PCZ-susp might be used without stringent need of PPC monitoring in patients without diarrhea, and an inadequate PPC pattern was associated with the development of diarrhea.